Diligence Events. Company, whether itself, or through its Affiliates, Third Party sublicensees, contractors, or Third Parties funded by Company under a research or service agreement, will use commercially reasonable efforts to achieve each of the milestone diligence events by the applicable completion date listed in the table below for the first Licensed Product for human therapeutic or prophylactic use in Field of Use B. Company will provide Cellscript with written notice within [***] days of first completion of each milestone diligence event for a Licensed Product for human therapeutic or prophylactic use in Field of Use B by Company or an Affiliate or Third Party sublicensee. MILESTONE DILIGENCE EVENT COMPLETION DATE 1. [***] [***]
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the diligence events by the applicable completion date listed in the table below for the first Licensed Product. DILIGENCE EVENT COMPLETION DATE [**] [ **] [**] [ **] [**] [ **] [**] [ **] [**].
Diligence Events. Licensee, itself and/or through its Affiliates, Sublicensees or Third Party subcontractors, shall achieve each Diligence Event set forth in the table below by the corresponding Achievement Date (each a “Diligence Event”) for the first Product for each Licensed Indication. [***] Diligence Event for each Licensed Indication, on a Licensed Indication-by-Licensed Indication basis Achievement Date [***] [***]
Diligence Events. The Company will use commercially reasonable efforts (either itself or through its Affiliates or sublicensees) to achieve each of the diligence events set forth below by the applicable completion date listed in the table below for the first Licensed Product. For purposes of this Section 2.3 and Section 3.4 below, the diligence or milestone event, as the case may be, associated with the initiation of a Phase II clinical trial for a Licensed Product shall be deemed achieved upon the initiation of any Phase II portion of a Phase I trial for such Licensed Product. DILIGENCE EVENT COMPLETION DATE Filing of IND for the Licensed Product July 1, 2007 [**] [**] [**] [**] [**] [**] [**] [**]
Diligence Events. The Company will use Commercially Reasonable Efforts to achieve each of the diligence events by the applicable completion date listed in Appendix A. In addition to usual and reasonable terms for termination, the University reserves the right to terminate the Agreement if Company fails to achieve one or more diligence events on or before their respective achievement date.
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the diligence events by the applicable completion date listed in the table below for the first product to be commercialized by the Company pursuant to this Agreement. DILIGENCE EVENT COMPLETION DATE Delivery to Penn of a preliminary business plan June 30, 2003 Raising at least an aggregate of $5 Million in equity investment capital by Company from qualified investors December 31, 2004 Filing of IND for first Licensed Product December 31, 2005 Initiation of Phase II clinical trials for first Licensed Product December 31, 2007 Initiation of Phase III clinical trials for first Licensed Product December 31, 2010 First commercial Sale of first Licensed Product December 31, 2013
Diligence Events. 7.2.1 Company shall achieve each Diligence Event set forth in Exhibit D hereto by the corresponding Achievement Date. Company may extend any Achievement Date for a Diligence Event by [*] increments, but not more than [*] times per Diligence Event, by making a [*] payment to Licensor prior to the expiration of the Achievement Date for such Diligence Event.
Diligence Events. The Company will use commercially reasonable efforts (either itself or through its Affiliates or sublicensees) to achieve each of the diligence events set forth below by the applicable completion date listed in the table below for the first Licensed Product. For purposes of this Section 2.3 and Section 3.3 below, the diligence or milestone event, as the case may be, associated with the initiation of a Phase II clinical trial for a Licensed Product shall be deemed achieved upon the initiation of any Phase II portion of a Phase I trial for such Licensed Product.
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the diligence events by the applicable completion date listed in the table below for the first Licensed Product. DILIGENCE EVENT COMPLETION DATE Delivery of a completed initial Business Plan to the Licensor Parties in a form acceptable to the Licensor Parties January 20, 2013 First dosing of first patient in a Phase III or other pivotal clinical trial for first licensed product Fifteen (15) months from the Execution Date of the Agreement Filing of NDA for first Licensed Product Thirty Nine (39) months from the Execution Date of the Agreement First Sale of the first Licensed Product as covered by the NDA March of 2017 (unless the Company is able to fast track FDA approval with the orphan designation)
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the Diligence Events by the applicable completion date listed in the table below for the first Licensed Product: DILIGENCE EVENT COMPLETION DATE [***] as set forth in [***] [***] [***] after Effective Date Receipt of IND approval for a Licensed Product 4 years after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date provided that with respect to the foregoing completion dates, to the extent any delay in meeting such completion dates is due to bona fide unforeseen discovery or development obstacles, and while Company is diligently advancing the program, such completion dates will be extended upon mutual agreement of the parties, which agreement will not be unreasonably withheld.
